Table 3.
New HIV-1 infections detected among participants enrolled in the follow-up study with available HIV test resultsa
Total | Vaccine | Placebo | |
---|---|---|---|
All | 28/421 (6.7%) | 15/205 (7.3%) | 13/216 (6.0%) |
Women | 17/190 (8.9%) | 7/90 (7.8%) | 10/100 (10.0%) |
Men | 11/231 (4.8%) | 8/115 (7.0%) | 3/116 (2.6%) |
Among the 422 participants enrolled in the follow-up study, one woman who received vaccine is pending HIV testing results.